Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs

Journal of Toxicological Sciences

Volumn 37, Issue 6, 2012, Pages 1157-1164

  Mogi, Masayuki ^a   Toda, Akiko ^a   Iwasaki, Kazuhide ^a   Kusumoto, Shogo ^a   Takehara, Hiromi ^b   Shimizu, Makiko ^b   Murayama, Norie ^b   Izumi, Hiroyuki ^a   Utoh, Masahiro ^a   Yamazaki, Hiroshi ^b  

^a SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Area under the plasma concentration time curve; Bioavailability; Combination probe; Liquid chromatography tandem mass spectrometry; Minipig

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; METOPROLOL; MIDAZOLAM; OMEPRAZOLE; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MICROMINIPIG; MINIPIG; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; TANDEM MASS SPECTROMETRY;

EID: 84870925399     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.37.1157     Document Type: Article

References (21)

1. Achour, B., Barber, J. and Rostami-Hodjegan, A. (2011): Cytochrome P450 Pig liver pie: determination of individual cytochrome P450 isoform contents in microsomes from two pig livers using liquid chromatography in conjunction with mass spectrometry. Drug Metab. Dispos., 39, 2130-2134.
2. Andersson, T., Miners, J.O., Veronese, M.E., Tassaneeyakul, W., Tassaneeyakul, W., Meyer, U.A. and Birkett, D.J. (1993): Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol., 36, 521-530.
3. Anzenbacher, P., Anzenbacherova, E., Zuber, R., Soucek, P. and Guengerich, F.P. (2002): Pig and minipig cytochromes P450. Drug Metab. Dispos., 30, 100-102.
4. Baranova, J., Anzenbacherova, E., Anzenbacher, P. and Soucek, P. (2005): Minipig cytochrome P450 2E1: Comparison with human enzyme. Drug Metab. Dispos., 33, 862-865.
5. Bertz, R.J. and Granneman, G.R. (1997): Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet., 32, 210-258.
6. He, M., Korzekwa, K.R., Jones, J.P., Rettie, A.E. and Trager, W.F. (1999): Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch. Biochem. Biophys., 372, 16-28.
7. Heizmann, P., Eckert, M. and Ziegler, W.H. (1983) Pharmacokinetics and bioavailability of midazolam in man. Br. J. Clin. Pharmacol., 16 Suppl. 1, 43S-49S.
8. Iwasaki, K., Murayama, N., Koizumi, R., Uno, Y. and Yamazaki, H. (2010): Comparison of cytochrome P450 3A enzymes in cynomolgus monkeys and humans. Drug Metab. Pharmacokinet., 25, 388-391.
9. Johnsson, G. and Regårdh, C.G. and Sölvell, L. (1975): Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol. Acta Pharmacol. Toxicol., 36, 31-44.
10. Johnson, J.A. and Burlew, B.S. (1996): Metoprolol metabolism via cytochrome P4502D6 in ethnic populations., Drug Metab. Dispos., 24, 350-355.
11. Kamimori, G.H., Karyekar, C.S., Otterstetter, R., Cox, D.S., Balkin, T.J., Belenky, G.L. and Eddington, N.D. (2002): The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. Int. J. Pharm., 234, 159-167.
12. Kaminsky, L.S. and Zhang, Z.Y. (1997): Human P450 metabolism of warfarin. Pharmacol. Ther., 73, 67-74.
13. Murayama, N., Kaneko, N., Horiuchi, K., Ohyama, K., Shimizu, M., Ito, K. and Yamazaki, H. (2009): Cytochrome P450-dependent drug oxidation activity of liver microsomes from Microminipigs, a possible new animal model for humans in non-clinical studies. Drug Metab. Pharmacokinet., 24, 404-408.
14. Perera, V., Gross, A.S. and McLachlan, A.J. (2012): Measurement of CYP1A2 activity: a focus on caffeine as a probe. Curr. Drug Metab., 13, 667-678.
15. Regårdh, C.G. (1986): Pharmacokinetics and metabolism of omeprazole in man. Scand J. Gastroenterol., 118, 99-104.
16. Robert, C., Wilson, C.S., Guengerich, F.P. and Arreto, C.D. (2010): Evolution of the scientific literature of cytochrome P450 from 1977 to 2008. Curr. Drug Metab., 11, 162-170.
17. Ryu, J.Y., Song, I.S., Sunwoo, Y.E., Shon, J.H., Liu, K.H., Cha, I.J., and Shin, J.G. (2007): Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin. Pharmacol. Ther., 82, 531-540.
18. Shetty, H.G., Fennerty, A.G. and Routledge, P.A. (1989): Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy. Clin. Pharmacokinet., 16, 238-253.
19. Sugiyama, A., Nakamura, Y. Akie, Y. Saito, H. Izumi, Y., Yamazaki, H., Kaneko, N. and Itoh K. (2011): Microminipig, a non-rodent experimental animal optimized for life science research: In vivo proarrhythmia models of drug-induced long QT syndrome: development of chronic atrioventricular block model of Microminipig. J. Pharmacol. Sci., 115, 122-126.
20. Turpault, S., Brian, W., Horn, R. V., Santoni, A., Poitiers, F., Donazzole, Y. and Boulenc, X. (2009): Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br. J. Clin. Pharmacol., 68, 928-935.
21. Uno, T., Niioka, T., Hayakari, M., Yasui-Furukori, N., Sugawara, K. and Tateishi, T. (2007): Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. Eur. J. Clin. Pharmacol., 63, 143-149.